Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists?

Cazzaniga ME, Munzone E, Montagna E, Pappagallo G.

Expert Rev Anticancer Ther. 2018 Jun 14. doi: 10.1080/14737140.2018.1489244. [Epub ahead of print]

PMID:
29902087
2.

Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer.

Palazzo A, Dellapasqua S, Munzone E, Bagnardi V, Mazza M, Cancello G, Ghisini R, Iorfida M, Montagna E, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2018 Feb 2. pii: S1526-8209(17)30737-1. doi: 10.1016/j.clbc.2018.01.010. [Epub ahead of print]

PMID:
29486983
3.

Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey.

Carnio S, Galetta D, Scotti V, Cortinovis DL, Antonuzzo A, Pisconti S, Rossi A, Martelli O, Cecere FL, Lunghi A, Del Conte A, Montagna ES, Topulli J, Pelizzoni D, Rapetti SG, Gianetta M, Pacchiana MV, Pegoraro V, Cataldo N, Bria E, Novello S.

Support Care Cancer. 2018 Jun;26(6):1841-1849. doi: 10.1007/s00520-017-4004-1. Epub 2017 Dec 21.

PMID:
29270827
4.

Molecular basis of basal cell carcinoma.

Montagna E, Lopes OS.

An Bras Dermatol. 2017 Jul-Aug;92(4):517-520. doi: 10.1590/abd1806-4841.20176544. Review.

5.

Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and Outcomes.

Montagna E, Pirola S, Maisonneuve P, De Roberto G, Cancello G, Palazzo A, Viale G, Colleoni M.

Clin Breast Cancer. 2018 Jun;18(3):e401-e405. doi: 10.1016/j.clbc.2017.07.003. Epub 2017 Jul 10.

PMID:
28778379
6.

Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy.

Montagna E, Vingiani A, Maisonneuve P, Cancello G, Contaldo F, Pruneri G, Colleoni M.

Breast. 2017 Aug;34:83-88. doi: 10.1016/j.breast.2017.05.009. Epub 2017 May 23.

PMID:
28544923
7.

The Role of APP in Structural Spine Plasticity.

Montagna E, Dorostkar MM, Herms J.

Front Mol Neurosci. 2017 May 10;10:136. doi: 10.3389/fnmol.2017.00136. eCollection 2017. Review.

8.

The Relationship Between Copper, Iron, and Selenium Levels and Alzheimer Disease.

Vaz FNC, Fermino BL, Haskel MVL, Wouk J, de Freitas GBL, Fabbri R, Montagna E, Rocha JBT, Bonini JS.

Biol Trace Elem Res. 2018 Feb;181(2):185-191. doi: 10.1007/s12011-017-1042-y. Epub 2017 May 13.

PMID:
28500578
9.

Electrochemical discrimination of mints: The last Chinese emperors Kuang Hsü and Hsüan T'ung monetary unification.

Doménech-Carbó A, Doménech-Carbó MT, Montagna E, Álvarez-Romero C, Lee Y.

Talanta. 2017 Jul 1;169:50-56. doi: 10.1016/j.talanta.2017.03.025. Epub 2017 Mar 18.

PMID:
28411821
10.

Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.

Montagna E, Palazzo A, Maisonneuve P, Cancello G, Iorfida M, Sciandivasci A, Esposito A, Cardillo A, Mazza M, Munzone E, Lai A, Goldhirsch A, Colleoni M.

Cancer Lett. 2017 Aug 1;400:276-281. doi: 10.1016/j.canlet.2017.01.027. Epub 2017 Jan 26.

PMID:
28131905
11.

Patients' Attitudes and Physicians' Perceptions Toward Maintenance Therapy for Advanced Non-Small-cell Lung Cancer: A Multicenter Italian Survey.

Pacchiana MV, Capelletto E, Carnio S, Gridelli C, Rossi A, Galetta D, Montagna ES, Bordi P, Ceribelli A, Cortinovis D, Scotti V, Martelli O, Valmadre G, Del Conte A, Miccianza A, Morena R, Rosetti F, Di Maio M, Ostacoli L, Novello S.

Clin Lung Cancer. 2017 Jul;18(4):381-387. doi: 10.1016/j.cllc.2016.10.002. Epub 2016 Nov 22.

PMID:
27965013
12.

Correction: Systemic Delivery of Recombinant Brain Derived Neurotrophic Factor (BDNF) in the R6/2 Mouse Model of Huntington's Disease.

Giampà C, Montagna E, Dato C, Melone MA, Bernardi G, Fusco FR.

PLoS One. 2016 Nov 23;11(11):e0166102. doi: 10.1371/journal.pone.0166102. eCollection 2016.

13.

Associations of Polymorphisms in Anti-Müllerian Hormone (AMH Ile49Ser) and its Type II Receptor (AMHRII -482 A>G) on Reproductive Outcomes and Polycystic Ovary Syndrome: a Systematic Review and Meta-Analysis.

Pabalan N, Montagna E, Singian E, Tabangay L, Jarjanazi H, Barbosa CP, Bianco B.

Cell Physiol Biochem. 2016;39(6):2249-2261. Epub 2016 Nov 7. Review.

14.

Amyloid precursor protein maintains constitutive and adaptive plasticity of dendritic spines in adult brain by regulating D-serine homeostasis.

Zou C, Crux S, Marinesco S, Montagna E, Sgobio C, Shi Y, Shi S, Zhu K, Dorostkar MM, Müller UC, Herms J.

EMBO J. 2016 Oct 17;35(20):2213-2222. Epub 2016 Aug 29.

15.

Ultrasound-Guided Vascular Access Simulator for Medical Training: Proposal of a Simple, Economic and Effective Model.

Fürst RV, Polimanti AC, Galego SJ, Bicudo MC, Montagna E, Corrêa JA.

World J Surg. 2017 Mar;41(3):681-686. doi: 10.1007/s00268-016-3757-x.

PMID:
27766394
16.

The advances and new technologies for the study of mitochondrial diseases.

Bianco B, Montagna E.

Einstein (Sao Paulo). 2016 Apr-Jun;14(2):291-3. doi: 10.1590/S1679-45082016MD3561. English, Portuguese.

17.

Metachronous primary uterine cancer surgically resected during Crizotinib treatment in a ALK-rearranged advanced lung adenocarcinoma.

Catino A, Misino A, Scattone A, Caldarola L, Petroni S, Logroscino A, Montagna ES, Serio G, Simone G, Galetta D.

Transl Lung Cancer Res. 2016 Feb;5(1):145-9. doi: 10.3978/j.issn.2218-6751.2016.01.04.

18.

Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study.

Balduzzi A, Bagnardi V, Sandri MT, Dellapasqua S, Cardillo A, Montagna E, Cancello G, Iorfida M, Ghisini R, Viale G, Intra M, Luini A, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2015 Oct;15(5):e257-62. doi: 10.1016/j.clbc.2015.03.007. Epub 2015 Apr 30.

PMID:
26362840
19.

Outcome and Medial Presentation of Breast Cancer: European Institute of Oncology Experience.

Montagna E, Bagnardi V, Rotmensz N, Viale G, Cancello G, Palazzo A, Galimberti V, Veronesi P, Luini A, Mastropasqua MG, Santillo B, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2015 Dec;15(6):440-7. doi: 10.1016/j.clbc.2015.07.003. Epub 2015 Jul 10.

PMID:
26255932
20.

Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer.

Cancello G, Bagnardi V, Sangalli C, Montagna E, Dellapasqua S, Sporchia A, Iorfida M, Viale G, Barberis M, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2015 Aug;15(4):259-65. doi: 10.1016/j.clbc.2015.03.002. Epub 2015 Mar 18.

PMID:
25933934
21.

Intraneuronal APP and extracellular Aβ independently cause dendritic spine pathology in transgenic mouse models of Alzheimer's disease.

Zou C, Montagna E, Shi Y, Peters F, Blazquez-Llorca L, Shi S, Filser S, Dorostkar MM, Herms J.

Acta Neuropathol. 2015 Jun;129(6):909-20. doi: 10.1007/s00401-015-1421-4. Epub 2015 Apr 11.

22.

Phase angle and handgrip strength are sensitive early markers of energy intake in hypophagic, non-surgical patients at nutritional risk, with contraindications to enteral nutrition.

Caccialanza R, Cereda E, Klersy C, Bonardi C, Cappello S, Quarleri L, Turri A, Montagna E, Iacona I, Valentino F, Pedrazzoli P.

Nutrients. 2015 Mar 11;7(3):1828-40. doi: 10.3390/nu7031828.

23.

Primary intraoperative transluminal angioplasty: a new approach to reduce the early failure of distal arteriovenous fistulas.

Napoli M, Lefons ML, Mangione D, Montagna C, Montagna E, Montinaro AM, Pati C, Sandri G, Sozzo E, Stefanizzi S.

J Vasc Access. 2015 May-Jun;16(3):250-4. doi: 10.5301/jva.5000327. Epub 2015 Jan 17.

PMID:
25613144
24.

Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy.

Montagna E, Bagnardi V, Viale G, Rotmensz N, Sporchia A, Cancello G, Balduzzi A, Galimberti V, Veronesi P, Luini A, Mastropasqua MG, Casadio C, Sangalli C, Goldhirsch A, Colleoni M.

Ann Oncol. 2015 Feb;26(2):307-13. doi: 10.1093/annonc/mdu528. Epub 2014 Nov 19.

PMID:
25411418
25.

Metronomic therapy and breast cancer: a systematic review.

Montagna E, Cancello G, Dellapasqua S, Munzone E, Colleoni M.

Cancer Treat Rev. 2014 Sep;40(8):942-50. doi: 10.1016/j.ctrv.2014.06.002. Epub 2014 Jun 18. Review.

PMID:
24998489
26.

Early dropout predictive factors in obesity treatment.

Michelini I, Falchi AG, Muggia C, Grecchi I, Montagna E, De Silvestri A, Tinelli C.

Nutr Res Pract. 2014 Feb;8(1):94-102. doi: 10.4162/nrp.2014.8.1.94. Epub 2014 Jan 29.

27.

Whole-body magnetic resonance imaging, metastatic breast cancer and pregnancy: a case report.

Montagna E, Peccatori F, Petralia G, Tomasi Cont N, Iorfida M, Colleoni M.

Breast. 2014 Jun;23(3):295-6. doi: 10.1016/j.breast.2014.01.012. Epub 2014 Feb 13. No abstract available.

PMID:
24529906
28.

Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.

Balduzzi A, Bagnardi V, Rotmensz N, Dellapasqua S, Montagna E, Cardillo A, Viale G, Veronesi P, Intra M, Luini A, Pruneri G, Mastropasqua G, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2014 Aug;14(4):258-64. doi: 10.1016/j.clbc.2013.10.019. Epub 2013 Oct 26.

PMID:
24325948
29.

Pathological features and survival outcomes of very young patients with early breast cancer: how much is "very young"?

Cancello G, Maisonneuve P, Mazza M, Montagna E, Rotmensz N, Viale G, Pruneri G, Veronesi P, Luini A, Gentilini O, Goldhirsch A, Colleoni M.

Breast. 2013 Dec;22(6):1046-51. doi: 10.1016/j.breast.2013.08.006. Epub 2013 Sep 30.

PMID:
24091127
30.

Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment.

Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Cameletti B, Quarleri L, Montagna E, Foli A, Milani P, Lavatelli F, Marena C, Merlini G.

JPEN J Parenter Enteral Nutr. 2014 Sep;38(7):891-4. doi: 10.1177/0148607113501328. Epub 2013 Sep 26.

PMID:
24072737
31.

Treatment of breast cancer in young women: do we need more aggressive therapies?

Cancello G, Montagna E.

J Thorac Dis. 2013 Jun;5 Suppl 1:S47-54. doi: 10.3978/j.issn.2072-1439.2013.06.10.

32.

The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?

Montagna E, Cancello G, Colleoni M.

Cancer Treat Rev. 2013 Dec;39(8):886-90. doi: 10.1016/j.ctrv.2013.04.007. Epub 2013 May 29. Review.

PMID:
23725877
33.

Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease.

Giampà C, Montagna E, Dato C, Melone MA, Bernardi G, Fusco FR.

PLoS One. 2013 May 20;8(5):e64037. doi: 10.1371/journal.pone.0064037. Print 2013. Erratum in: PLoS One. 2016 Nov 23;11(11):e0166102.

34.

Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.

Leuti A, Laurenti D, Giampà C, Montagna E, Dato C, Anzilotti S, Melone MA, Bernardi G, Fusco FR.

Neurobiol Dis. 2013 Apr;52:104-16. doi: 10.1016/j.nbd.2012.11.016. Epub 2012 Dec 7.

PMID:
23220622
35.

Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.

Montagna E, Maisonneuve P, Rotmensz N, Cancello G, Iorfida M, Balduzzi A, Galimberti V, Veronesi P, Luini A, Pruneri G, Bottiglieri L, Mastropasqua MG, Goldhirsch A, Viale G, Colleoni M.

Clin Breast Cancer. 2013 Feb;13(1):31-9. doi: 10.1016/j.clbc.2012.09.002. Epub 2012 Oct 24.

PMID:
23098574
36.

Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Iorfida M, Mazza M, Balduzzi A, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M.

Ann Oncol. 2013 Mar;24(3):661-8. doi: 10.1093/annonc/mds430. Epub 2012 Sep 28.

PMID:
23022996
37.

Neoadjuvant therapy for ER-positive breast cancers.

Colleoni M, Montagna E.

Ann Oncol. 2012 Sep;23 Suppl 10:x243-8.

PMID:
22987970
38.

Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.

Montagna E, Cancello G, Bagnardi V, Pastrello D, Dellapasqua S, Perri G, Viale G, Veronesi P, Luini A, Intra M, Calleri A, Rampinelli C, Goldhirsch A, Bertolini F, Colleoni M.

Clin Breast Cancer. 2012 Jun;12(3):207-14. doi: 10.1016/j.clbc.2012.03.008. Epub 2012 Apr 20.

PMID:
22520733
39.

Invasive lobular breast cancer: subtypes and outcome.

Iorfida M, Maiorano E, Orvieto E, Maisonneuve P, Bottiglieri L, Rotmensz N, Montagna E, Dellapasqua S, Veronesi P, Galimberti V, Luini A, Goldhirsch A, Colleoni M, Viale G.

Breast Cancer Res Treat. 2012 Jun;133(2):713-23. doi: 10.1007/s10549-012-2002-z. Epub 2012 Mar 8.

PMID:
22399188
40.

Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.

Dellapasqua S, Bagnardi V, Bertolini F, Sandri MT, Pastrello D, Cancello G, Montagna E, Balduzzi A, Mancuso P, Luini A, Goldhirsch A, Colleoni M.

Breast. 2012 Jun;21(3):309-13. doi: 10.1016/j.breast.2012.01.015. Epub 2012 Feb 16.

PMID:
22341133
41.

[A case of Xanthinuria in a patient with marked hypouricemia].

Martella V, Sozzo E, Montagna E, Stefanizzi S, Cito A, Marinello E, Terzuoli L, Micheli V, Napoli M.

G Ital Nefrol. 2011 Nov-Dec;28(6):648-53. Italian.

PMID:
22167616
42.

Outcome of special types of luminal breast cancer.

Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua MG, Luini A, Veronesi P, Intra M, Montagna E, Cancello G, Cardillo A, Mazza M, Perri G, Iorfida M, Pruneri G, Goldhirsch A, Viale G.

Ann Oncol. 2012 Jun;23(6):1428-36. doi: 10.1093/annonc/mdr461. Epub 2011 Oct 29.

PMID:
22039080
43.

Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis.

Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Cameletti B, Montagna E, Russo P, Foli A, Milani P, Lavatelli F, Merlini G.

Ann Hematol. 2012 Mar;91(3):399-406. doi: 10.1007/s00277-011-1309-x. Epub 2011 Aug 9.

PMID:
21826471
44.

Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation.

Montagna E, Bagnardi V, Rotmensz N, Viale G, Cancello G, Mazza M, Cardillo A, Ghisini R, Galimberti V, Veronesi P, Monti S, Luini A, Raviele PR, Mastropasqua MG, Goldhirsch A, Colleoni M.

Breast Cancer Res Treat. 2011 Oct;129(3):867-75. doi: 10.1007/s10549-011-1697-6. Epub 2011 Aug 6.

PMID:
21822638
45.

Breast cancer subtypes and outcome after local and regional relapse.

Montagna E, Bagnardi V, Rotmensz N, Viale G, Renne G, Cancello G, Balduzzi A, Scarano E, Veronesi P, Luini A, Zurrida S, Monti S, Mastropasqua MG, Bottiglieri L, Goldhirsch A, Colleoni M.

Ann Oncol. 2012 Feb;23(2):324-31. doi: 10.1093/annonc/mdr129. Epub 2011 Apr 27.

PMID:
21525402
46.

Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Dellapasqua S, Iorfida M, Cardillo A, Veronesi P, Luini A, Intra M, Gentilini O, Scarano E, Goldhirsch A, Colleoni M.

Breast Cancer Res Treat. 2011 Jun;127(3):713-20. doi: 10.1007/s10549-011-1465-7. Epub 2011 Mar 31.

PMID:
21452022
47.

Receptor status (ER, PgR and HER2) discordance between primary tumor and locoregional recurrence in breast cancer.

Zurrida S, Montagna E, Naninato P, Colleoni M, Goldhirsch A.

Ann Oncol. 2011 Feb;22(2):479-80. doi: 10.1093/annonc/mdq688. No abstract available.

48.

The TNM classification of breast cancer: need for change.

Arnone P, Zurrida S, Viale G, Dellapasqua S, Montagna E, Arnaboldi P, Intra M, Veronesi U.

Updates Surg. 2010 Oct;62(2):75-81. doi: 10.1007/s13304-010-0014-y. No abstract available.

PMID:
20845013
49.

Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer.

Torrisi R, Montagna E, Scarano E, Dellapasqua S, Cancello G, Iorfida M, Luini A, Veronesi P, Viale G, Goldhirsch A, Colleoni M.

Breast. 2011 Feb;20(1):34-8. doi: 10.1016/j.breast.2010.06.005. Epub 2010 Jul 16.

PMID:
20638282
50.

Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features.

Montagna E, Bagnardi V, Rotmensz N, Viale G, Pruneri G, Veronesi P, Cancello G, Balduzzi A, Dellapasqua S, Cardillo A, Luini A, Zurrida S, Gentilini O, Mastropasqua MG, Bottiglieri L, Iorfida M, Goldhirsch A, Colleoni M.

Breast Cancer Res Treat. 2010 Dec;124(3):689-99. doi: 10.1007/s10549-010-1027-4. Epub 2010 Jul 13.

PMID:
20625816

Supplemental Content

Loading ...
Support Center